Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 101 clinical trials
Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer (BREASTIMMU02)

in combination with trastuzumab + paclitaxel in HER2-positive early stage breast cancer patients. Breastimmune02 is a multicenter, randomized, open-label, Phase II trial. Operable HER2+ breast cancer

platelet count
gilbert's syndrome
cyclophosphamide
breast cancer
neutrophil count
  • 15 views
  • 23 Mar, 2022
  • 13 locations
A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of Trastuzumab Deruxtecan (DS-8201a) With or Without Anastrozole for HER2 Low Hormone Receptor Positive (HR+) Breast Cancer in the Neoadjuvant Setting

This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab attaches to HER2 expressed at low levels …

  • 0 views
  • 11 Oct, 2022
  • 8 locations
Evaluating Harms and Benefits of Endocrine Therapy in Patients ≥70 Years of Age With Lower Risk Breast Cancer

in older patients with lower-risk early-stage breast cancer. Therefore, we propose a randomised, multicentre trial evaluating harms and benefits of endocrine therapy in patients 70 years of age with

estrogen
hormone therapy
mastectomy
progesterone receptor
endocrine therapy
  • 0 views
  • 07 Oct, 2022
  • 1 location
Specimen PET-CT Imaging for Intraoperative Margin Assessment in Breast Cancer (BrIMA)

Breast-conserving surgery (BCS) has become the standard-of-care for surgical management of the majority of women with early-stage breast cancer. Successful BCS entails excision of the tumor with

breast cancer staging
breast-conserving surgery
mammogram
early-stage breast cancer
  • 0 views
  • 04 Oct, 2022
  • 1 location
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

treatment of early stage breast cancer before surgery (neoadjuvant therapy). Ribociclib and tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Trastuzumab

  • 0 views
  • 30 May, 2022
  • 1 location
Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.

An explanatory study comparing complementary treatment to breast conservative surgery with radiation therapy DCIS, T1-T2 N0 M0 (AJCC v8) 1 week schedule vs 3.1 weeks standard schedule, in order to determine the equivalence of local tumor control, survival, acute and chronic toxicity. Shorter curse of radiation therapy may lead to …

cancer
breast carcinoma
tumor cells
breast-conserving surgery
breast cancer
  • 0 views
  • 21 Apr, 2022
  • 1 location
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients

(Arimidex®) and Letrozole (Femara®) are AIs that are approved by the Food and Drug Administration (FDA). They have been used since 2005 to treat women with early stage breast cancer. When given

primary tumor
mammogram
endocrine therapy
aromatase inhibitor
breast cancer staging
  • 19 views
  • 13 May, 2022
  • 1 location
Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast

An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Neratinib Followed by Weekly Paclitaxel and Carboplatin Plus Neratinib in Early Stage Triple-Negative Breast Cancer Patients Who Exhibit Enhanced HER2 Signaling by Live Cell HER2 Signaling Transduction Analysis (FACT-2)

metastasis
immunohistochemistry
gilbert's syndrome
mammogram
neutrophil count
  • 0 views
  • 25 Jan, 2021
  • 1 location
4FMFES-PET Imaging of ER+ Advanced Breast Cancers

FES. It resulted in a significantly improved tumor contrast and tumor detectability using 4FMFES-PET leading to increased diagnosis confidence in early-stage breast cancer compared to FES-PET. Those

  • 0 views
  • 04 Oct, 2022
  • 1 location
Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors

This phase II trial studies how well oxaloacetate works in reducing cognitive complaints in stage 0-IIIA breast cancer survivors. Oxaloacetate is a natural substance found in the body and is available as a nutritional supplement. Giving oxaloacetate may reduce inflammation in the brain that could be contributing to cognitive complaints …

  • 0 views
  • 15 Oct, 2021
  • 1 location